Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik J Bergstralh

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Obesity Research|August 15, 2003
Use of glucose, insulin, and C-reactive protein to determine need for glucose tolerance testingWarren G Thompson, Erik J Bergstralh, Jeffrey M Slezak
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 10, 2002
Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathyJames V Donadio, Erik J Bergstralh, Joseph P Grande, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 2, 2003
Urinary albumin to osmolality ratio predicts 24-hour urine albumin excretion in diabetes mellitusGeeta G Gyamlani, Erik J Bergstralh, Jeffrey M Slezak, et al.
Journal of the American Society of Nephrology : JASN|March 29, 2001
A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathyJames V Donadio, Timothy S Larson, Erik J Bergstralh, et al.
The Journal of Urology|July 20, 2002
Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient ageSusan D Sweat, Erik J Bergstralh, Jeffrey Slezak, et al.
The Journal of Urology|October 9, 2003
The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomyJohn F Ward, Michael L Blute, Jeffrey Slezak, et al.
The Journal of Urology|December 18, 2001
Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variablesWeber K Lau, Erik J Bergstralh, Michael L Blute, et al.
BJU International|March 30, 2005
Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcomeJohn F Ward, Jeffrey M Slezak, Michael L Blute, et al.
The Journal of Urology|November 13, 2004
Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapyJohn F Ward, Horst Zincke, Erik J Bergstralh, et al.
Genes, Chromosomes & Cancer|July 12, 2002
Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancerNorihiko Tsuchiya, Jeffrey M Slezak, Michael M Lieber, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Obesity Research|August 15, 2003
Use of glucose, insulin, and C-reactive protein to determine need for glucose tolerance testingWarren G Thompson, Erik J Bergstralh, Jeffrey M Slezak
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 10, 2002
Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathyJames V Donadio, Erik J Bergstralh, Joseph P Grande, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 2, 2003
Urinary albumin to osmolality ratio predicts 24-hour urine albumin excretion in diabetes mellitusGeeta G Gyamlani, Erik J Bergstralh, Jeffrey M Slezak, et al.
Journal of the American Society of Nephrology : JASN|March 29, 2001
A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathyJames V Donadio, Timothy S Larson, Erik J Bergstralh, et al.
The Journal of Urology|July 20, 2002
Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient ageSusan D Sweat, Erik J Bergstralh, Jeffrey Slezak, et al.
The Journal of Urology|October 9, 2003
The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomyJohn F Ward, Michael L Blute, Jeffrey Slezak, et al.
The Journal of Urology|December 18, 2001
Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variablesWeber K Lau, Erik J Bergstralh, Michael L Blute, et al.
BJU International|March 30, 2005
Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcomeJohn F Ward, Jeffrey M Slezak, Michael L Blute, et al.
The Journal of Urology|November 13, 2004
Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapyJohn F Ward, Horst Zincke, Erik J Bergstralh, et al.
Genes, Chromosomes & Cancer|July 12, 2002
Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancerNorihiko Tsuchiya, Jeffrey M Slezak, Michael M Lieber, et al.
Pageof 4